Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06986148

Comparing Antibiotic Treatment Strategies for Children With Pneumonia in Outpatient Settings: (STAMPP)

The goal of this clinical trial is to determine if a "watch and wait" antibiotic strategy, called Safety Net Antibiotic Prescribing (SNAP), can safely reduce unnecessary antibiotic use while ensuring that children diagnosed with community-acquired pneumonia get better from their illness. The main aims of this study are:

* To compare the effectiveness of SNAP versus immediate antibiotic prescribing in children with mild community-acquired pneumonia (CAP) * To identify which patient groups benefit most from the SNAP strategy * To identify factors that shape implementation of each prescribing strategy.

Researchers will compare the SNAP strategy (where parents or guardians are instructed to give antibiotics only if their child is not improving after 72 hours, or sooner if they are worsening) to the immediate antibiotic prescribing strategy (where parents or guardians are instructed to give the antibiotics right after their healthcare visit) to see if one strategy is more effective than the other.

Participants will be randomly assigned to either the immediate antibiotic group or the SNAP group at enrollment. Participation lasts 14 days with follow-up surveys at 4, 7, and 14 days after enrollment.

Recruiting

Interested in participating?

Request Info

Key information

Age range

12 month–71 month

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Children's Healthcare of Atlanta, Atlanta, Georgia, United States

Loading trial locations.

About this study

This study is a multicenter, Hybrid Type-1effectiveness-implementation randomized clinical trial (RCT) designed to evaluate the effectiveness of a "Safety Net Antibiotic Prescribing" (SNAP) strategy versus an immediate antibiotic prescribing strategy for young children 12 months to <6 years of age with community-acquired pneumonia (CAP) who are treated as outpatients.

This study will recruit eligible patients from approximately 19 clinical sites consisting of pediatric emergency departments (EDs), primary care offices, and urgent care centers within the United States and enroll up to 2,000 patients. Patient recruitment will occur over a 3.5-year period. Participants will be identified and screened during routine visits at the clinical sites.

Through an online system, participants will be randomized to either the immediate antibiotic group or the SNAP group. All participants will receive a prescription for antibiotics as per usual care from their treating clinician.

The parents or guardians of the participants will be asked to complete an online survey on Days 4 and 14 (+/- 2 days) to collect data for the secondary outcomes, including quality of life, satisfaction, and return visits. On Day 7 (+/- 2 days), the parents or guardians of the participants will be contacted by phone to collect data for the primary outcome, focusing on clinical improvement and antibiotic use.

Acceptability and feasibility will be assessed with parent or guardian and clinician surveys and interviews. Parents or guardians will be surveyed at Day 14 and a subset will be invited for interviews within a month of the final follow-up visit. Clinicians will be surveyed, and a subset will be interviewed at the conclusion of the trial.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Aims 1 and 2:
  • Presenting with signs and symptoms of lower respiratory tract infection
  • Diagnosed with community-acquired pneumonia (CAP) by a clinician
  • The treating clinician intends to prescribe antibiotics for CAP, AND
  • Well enough, as determined by the clinician at the time of the study enrollment visit, to be managed as an outpatient.
  • Aim 3:
  • Parent/guardian of child enrolled in the trial, OR
  • Clinician who makes prescribing decision at the study site, OR
  • Other practice-based parties (e.g. nurses, pharmacists, medical assistants, practice leaders) at study sites who can comment on the implementation of each prescribing strategy.

Exclusion criteria

  • Aims 1 and 2:
  • Hospitalization within the previous 7 days
  • Oxygen saturation below 90%, if measured
  • Incomplete immunization status (e.g., lacking at least 3 doses of the pneumococcal vaccines, typically given as part of the 2-, 4-, and 6-month vaccinations)
  • Chronic medical conditions that increase the risk of bacterial CAP (e.g., chronic lung disease, cystic fibrosis, sickle cell disease),
  • Substantially immunocompromised status (e.g., immunodeficiency, active cancer treatment, organ transplant with concurrent immunosuppressive agents)
  • Receipt of oral or parenteral antibiotics within the previous 7 days
  • Diagnosis of complicated pneumonia (e.g., empyema, lung abscess)
  • Known bacterial source of infection warranting immediate antibiotics
  • Pneumonia diagnosis within the previous 6 months, OR
  • Prior enrollment in the trial
  • Inability of the parent or guardian to speak English or Spanish
  • Aim 3:
  • Inability of the parent or guardian to speak English

Treatment and study plan

Immediate Antibiotic Prescribing Group Instructions

Other

Children randomized to the immediate antibiotic prescribing group will receive an antibiotic prescription with instructions to fill and administer the antibiotics.

Safety Net Antibiotic Prescribing (SNAP) Group Instructions

Other

For children randomized to the SNAP group, their parents or guardians will receive a prescription for antibiotics, but will be told not to administer the antibiotic unless their child's symptoms show no improvement at 72 hours or worsen within 72 hours.

Primary outcomes

  1. Clinical Improvement

    Time frame: From enrollment to day 7

    Clinical improvement at 7 days after the index visit, defined as parent-reported (a) perception of overall improvement, (b) no worsening of fever, work of breathing, concerning changes in activity, or decreased oral intake, (c) no new antibiotic use or hospitalization following the index visit, and (d) improvement in at least one key pneumonia symptom in (b).

  2. Antibiotic Use

    Time frame: From enrollment to day 7

    Antibiotic use through 7 days after the index visit, defined as Parent-reported antibiotic use (yes/no) at 7 days.

Secondary outcomes

  1. Antibiotic Exposure

    Time frame: From enrollment to day 14

    Antibiotic exposure, defined as the number of days antibiotics were consumed through day 7 and day 14.

  2. Clinical Improvement

    Time frame: From enrollment to day 14

    Clinical improvement at day 4 and day 14. Clinical improvement is defined as parent-reported perception of overall improvement, no worsening of fever, work of breathing, concerning changes in activity, or decreased oral intake, no new antibiotic use or hospitalization following the index visit, and improvement in at least one of these key pneumonia symptoms. Symptom improvement is assessed on an ordinal scale with "Much Worse" as the minimum measurement and "Much Better" as the maximum measurement.

  3. Parent Satisfaction

    Time frame: From enrollment to day 14

    Parent-reported satisfaction with the treatment strategy at day 14. Parent-reported satisfaction with the treatment strategy is assessed on an ordinal scale with "Very Dissatisfied" as the minimum measurement and "Very Satisfied" as the maximum measurement.

  4. Quality of Life Measures

    Time frame: From enrollment to day 14

    Quality of life, defined by parent/guardian using the Pediatric Quality of Life Inventory (PedsQL) at days 7 and 14

  5. Return to Care

    Time frame: From enrollment to day 14

    Parent-reported return to medical care after index visit and reason for return

Other outcomes

  1. Antibiotic-associated Adverse Events

    Time frame: From enrollment to day 14

    Rash, diarrhea, diaper dermatitis, oral thrush, vomiting, anaphylaxis

Study contacts

Contact information is provided by the study sponsor or research team.

Julia Szymczak, PhD

CONTACT

[email protected]

Todd Florin, MD, MSCE

CONTACT

[email protected]

312-227-6675

Sponsors and collaborators

Lead sponsor

Ann & Robert H Lurie Children's Hospital of Chicago

Other

Collaborators

  • Patient-Centered Outcomes Research Institute

Registry information

Official study title

Comparing Antibiotic Treatment Strategies for Children With Community-Acquired Pneumonia in Outpatient Settings (Safety-Net Antibiotic Prescribing to Manage Pediatric Pneumonia [STAMPP])

Acronym: STAMPP

Important dates

Study start
2025
Primary completion
2029
Study completion
2029
First posted
May 22, 2025
Registry last updated
Jan 27, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.